Leading of large multi-county and multi-workstream engagements across health economics, real-world evidence and HTA. Strategy development, leading HTA processes and HTA company representation on behalf of clients. Business development, line management and company co-lead for EMEA HTA CoE. Key disease areas: RA, CSA-AKI, psoriasis, ulcerative colitis, MDSI, diabetes, DPNKey workstreams: NICE, SMC, NCPE STA, BI modelling, CE modelling (DES, PSM, Markov), SLR, NMA, clinician survey, manuscript and conference poster publication

Member of the Inflammation team supporting HEOR, Market Access and HTA strategy and implementation.

Company representation at NICE Appraisal Committee MeetingCost-effectiveness modelling (HCC, BCC, hyperkalaemia)Budget impact modelling (Glaucoma, hyperkalaemia)HTA submission and support for NICE (HCC, BCC, hyperkalaemia, AML, RA), SMC (HCC, RA, BCC), NCPE and Nordic marketsReal-world database analysis and economic modelling (atopic dermititis)Manuscript and conference poster development (Glaucoma, oncology, diabetes, autoimmune disease, atopic dermititis)Clinical coding (immunisation)Literature review (diabetes, oncology, autoimmune)Forecasting (diabetes, oncology, autoimmune)Burden of illness analysis for government and senior audiences (diabetes, oncology, autoimmune) Proposal developmentProject management, including multi-country and multi-team projectsMentoring / line management

Database analyses: CPRD (multiple indications in TSC), THIN (diabetes)Multi-country budget impact modelling: diabetes (UK, Canada), rheumatoid arthritis (UK, France, Italy, Belgium, Slovakia, Hungary)Cost-effectiveness modelling: gastric cancer (UK, US)Cost-minimisation modelling: diabetes (UK)Budget impact modelling: glaucoma devices (UK)Discrete event simulation modelling (cost-utility): rheumatoid arthritis (UK, France, Italy, Belgium), AMD (UK model critique)HTA submissions and support: Basal cell carcinoma (NICE, SMC), rheumatoid arthritis (Italy, Belgium, France, UK, Slovakia, Hungary)Manuscript and conference poster publications (glaucoma, TSC)iPad app development: Diabetes (UK, US, Canada)Proposal writing

Cost-effectiveness modelling: oncology (US)Budget-impact modelling: diabetes (UK, Canada)Database analyses: CPRD (multiple indications in TSC)HTA reimbursement support: SMC (oncology), NICE (oncology), AWMSG (oncology)Systematic literature review (SLR): rheumatoid arthritisProposal writing

Economic modelling for utilisation in healthcare and pharmaceutical industry, including budget impact and cost effectiveness models. Support in the development and maintenance of company market access applications.Market access and horizon scanning activities for both current and pipeline therapiesMSc dissertation placement (4 months plus 2 months travelling after completion)

Planning and deliverance of pharmaceutical, technical and regulatory aspects of phase 1, first in human, clinical trials on behalf of various global pharmaceutical companies. These include interaction, mechanism of action and dose determination studies. Trained to ICH GCP and GMP.Development and periodic review of pharmacy related standard operating procedures to ensure compliance with MHRA regulations, GMP and company guidelines.

Lead surgical pharmacist covering High dependency Unit (HDU), Intensive Care Unit (ICU), surgical recovery unit, gastroenterology and endocrinology.Member of the Consultant Nutrition team, actively advising on the use and constituents of Total Parenteral Nutrition (TPN)Review and writing of hospital surgical policies, guidelines, patient group directives and SOP’s.Management of rotational pharmacists covering colo-rectal and orthopaedic wards

Managing all aspects of pharmacy and store operations.43% growth in dispensing business year to date for 2007/8 (number one rank in company)31% growth in sales year to date for 2007/8 (number two rank in company)